Finanzen von Regenxbio Inc (RGNX)RGNXRegenxbio Inc

Evaluating the bottom line, REGENXBIO Inc. maintains a gross margin of 99.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 27.09%, while the net margin is 21.02%. These profitability ratios, combined with a Return on Equity (ROE) of -137.63%, provide a clear picture of how effectively RGNX converts its operational activities into shareholder value.

In the context of the broader market, RGNX competes directly with industry leaders such as PBYI and DBVT. With a market capitalization of $534.05M, it holds a significant position in the sector. When comparing efficiency, RGNX's gross margin of 99.04% stands against PBYI's 77.92% and DBVT's 100.00%. Such benchmarking helps identify whether REGENXBIO Inc. is trading at a premium or discount relative to its financial performance.

Regenxbio's financial performance shows volatility, with a recent EPS of 0.43, a significant surprise of 258.33%. The gross margin for Q2 2026 was 99.04%, indicating strong profitability on sales. However, the company has faced net losses, with a net income of -90.05 million in Q1 2026.